Table 2. Description of MAT therapy in study participants.

Drug	Frequency (%)	Mean dose ± SD (mg)	Range (mg)
Participants on MAT before they found out that they were pregnant (n=35)
Methadone	23 (65.7)	102.7±34.2	50 - 210
Buprenorphine + Naloxone	12 ( 34.3)	16±8.3	4 - 32
Participants who began MAT after pregnancy recognition (n=17)
Methadone	1 (5.9)	75
Buprenorphine	16 (94.1)	17±6.28	8 - 32
MAT use at the admission for labor and delivery (n=52*)
Methadone	24 (46.2)	125.8±35.6	55 - 210
Buprenorphine	28 (53.8)	22.8±4.2	8 - 32

^*Overall, 53 patients were classified into the MAT group: 52 were on methadone or buprenorphine and 1 was on Oxycodone^® throughout the pregnancy